Chronic Lymphocytic Leukemia (CLL) affects countless lives, making it the most prevalent form of leukemia in adults, impacting both blood and bone marrow. On the 1st of September, we join hands with the global community to observe World CLL Day, a time dedicated to raising awareness about the challenges faced by patients battling this condition.
This year focuses on a crucial aspect often overlooked: the mental health struggles that accompany CLL, emphasizing not only physical well-being but also mental resilience. As we work towards comprehensive care, we are excited to share our contribution in this journey.
Our goal is to improve the CLL patients’ journey by developing the technology GEUS (Genome and Epigenome Unified Sequencing) which determines the molecular profiles of each patient in a rapid, precise and efficient manner. By accelerating decision-making processes and tailoring treatments to individual needs, GEUS holds the potential to significantly lighten the burden on each patient.
For more information about the World CLL Day 2023 campaign: https://www.wclld.org/campaign-material-2023/
